Primary Treatment: Talquetamab · No Placebo Group · Phase 3
Arm A: Talquetamab
Experimental Group · 1 Intervention: Talquetamab · Intervention Types: Drug
Arm B: Belantamab Mafodotin
ActiveComparator Group · 1 Intervention: Belantamab Mafodotin · Intervention Types: Drug
Screening: ~3 weeks
Reporting: up to 4 years
Closest Location: New Jersey Hematology Oncology Ass. · Brick, NJ
N/AFirst Recorded Clinical Trial
1 TrialsResearching Multiple Myeloma
0 CompletedClinical Trials
Who is running the clinical trial?
Janssen Research & Development, LLCLead Sponsor
916 Previous Clinical Trials
6,326,652 Total Patients Enrolled
62 Trials studying Multiple Myeloma
16,987 Patients Enrolled for Multiple Myeloma
Janssen Research & Development, LLC Clinical TrialStudy DirectorJanssen Research & Development, LLC
705 Previous Clinical Trials
3,899,947 Total Patients Enrolled
45 Trials studying Multiple Myeloma
12,125 Patients Enrolled for Multiple Myeloma
Age 18+ · All Participants · 5 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:
You have progressive disease based on the investigator's determination of response by IMWG criteria on or after their last regimen.
You have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 at screening.
You are a female participant of childbearing potential who has a negative serum pregnancy test at screening, and who agrees to further serum or urine pregnancy tests during the study and within 6 months after receiving the last dose of study treatment.
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.